Lakewood-Amedex Biotherapeutics Inc. (LABT) Ratios
Lakewood-Amedex Biotherapeutics Inc. Ratios
LABT's free cash flow for Q2 2026 was $-2.10M. For the 2026 fiscal year, LABT's free cash flow was increased by $0.00 and operating cash flow was $-2.10M. See a summary of the company’s cash flow.
| Ratios | Dec 25 |
|---|---|
| Liquidity Ratios | |
| Current Ratio | 0.13 |
| Quick Ratio | 0.13 |
| Cash Ratio | 0.10 |
| Solvency Ratio | -1.52 |
| Operating Cash Flow Ratio | -0.81 |
| Short-Term Operating Cash Flow Coverage | -1.30 |
| Net Current Asset Value | $ -2.14M |
| Leverage Ratios | |
| Debt-to-Assets Ratio | 3.45 |
| Debt-to-Equity Ratio | -0.85 |
| Debt-to-Capital Ratio | -5.46 |
| Long-Term Debt-to-Capital Ratio | 0.00 |
| Financial Leverage Ratio | -0.25 |
| Debt Service Coverage Ratio | -2.27 |
| Interest Coverage Ratio | -37.39 |
| Debt to Market Cap | 0.01 |
| Interest Debt Per Share | 1.26 |
| Net Debt to EBITDA | -0.39 |
| Profitability Margins | |
| Gross Profit Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Profit Margin | 0.00% |
| Pretax Profit Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Continuous Operations Profit Margin | 0.00% |
| Net Income Per EBT | 100.00% |
| EBT Per EBIT | 102.00% |
| Return on Assets (ROA) | -798.93% |
| Return on Equity (ROE) | 195.85% |
| Return on Capital Employed (ROCE) | 196.12% |
| Return on Invested Capital (ROIC) | 1240.11% |
| Return on Tangible Assets | -798.93% |
| Earnings Yield | -3.19% |
| Efficiency Ratios | |
| Receivables Turnover | 0.00 |
| Payables Turnover | 0.00 |
| Inventory Turnover | 0.00 |
| Fixed Asset Turnover | 0.00 |
| Asset Turnover | 0.00 |
| Working Capital Turnover Ratio | 0.00 |
| Cash Conversion Cycle | 0.00 |
| Days of Sales Outstanding | 0.00 |
| Days of Inventory Outstanding | 0.00 |
| Days of Payables Outstanding | 0.00 |
| Operating Cycle | 0.00 |
| Cash Flow Ratios | |
| Operating Cash Flow Per Share | -1.40 |
| Free Cash Flow Per Share | -1.40 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 |
| Operating Cash Flow Coverage Ratio | -1.17 |
| Operating Cash Flow to Sales Ratio | 0.00 |
| Free Cash Flow Yield | -1.61% |
| Valuation Ratios | |
| Price-to-Earnings (P/E) Ratio | -31.34 |
| Price-to-Sales (P/S) Ratio | 0.00 |
| Price-to-Book (P/B) Ratio | -61.36 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -61.99 |
| Price-to-Operating Cash Flow Ratio | -61.99 |
| Price-to-Earnings Growth (PEG) Ratio | 0.52 |
| Enterprise Value Multiple | -33.63 |
| Enterprise Value | 121.97M |
| EV to EBITDA | -33.63 |
| EV to Sales | 0.00 |
| EV to Free Cash Flow | -62.72 |
| EV to Operating Cash Flow | -62.72 |
| Tangible Book Value Per Share | -1.41 |
| Shareholders’ Equity Per Share | -1.41 |
| Tax and Other Ratios | |
| Effective Tax Rate | 0.00 |
| Revenue Per Share | 0.00 |
| Net Income Per Share | -2.76 |
| Tax Burden | 1.00 |
| Interest Burden | 1.03 |
| Research & Development to Revenue | 0.00 |
| SG&A to Revenue | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 |
| Income Quality | 0.51 |
Currency in USD
